Literature DB >> 25592387

MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics.

Marie Helene Schernthaner-Reiter1, Giampaolo Trivellin, Constantine A Stratakis.   

Abstract

Pituitary adenomas are a common feature of a subset of endocrine neoplasia syndromes, which have otherwise highly variable disease manifestations. We provide here a review of the clinical features and human molecular genetics of multiple endocrine neoplasia (MEN) type 1 and 4 (MEN1 and MEN4, respectively) and Carney complex (CNC). MEN1, MEN4, and CNC are hereditary autosomal dominant syndromes that can present with pituitary adenomas. MEN1 is caused by inactivating mutations in the MEN1 gene, whose product menin is involved in multiple intracellular pathways contributing to transcriptional control and cell proliferation. MEN1 clinical features include primary hyperparathyroidism, pancreatic neuroendocrine tumours and prolactinomas as well as other pituitary adenomas. A subset of patients with pituitary adenomas and other MEN1 features have mutations in the CDKN1B gene; their disease has been called MEN4. Inactivating mutations in the type 1α regulatory subunit of protein kinase A (PKA; the PRKAR1A gene), that lead to dysregulation and activation of the PKA pathway, are the main genetic cause of CNC, which is clinically characterised by primary pigmented nodular adrenocortical disease, spotty skin pigmentation (lentigines), cardiac and other myxomas and acromegaly due to somatotropinomas or somatotrope hyperplasia.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25592387      PMCID: PMC4497946          DOI: 10.1159/000371819

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  183 in total

1.  Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.

Authors:  J C Donovan; A Milic; J M Slingerland
Journal:  J Biol Chem       Date:  2001-08-29       Impact factor: 5.157

2.  The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation.

Authors:  C Heppner; K Y Bilimoria; S K Agarwal; M Kester; L J Whitty; S C Guru; S C Chandrasekharappa; F S Collins; A M Spiegel; S J Marx; A L Burns
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

Review 3.  Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation.

Authors:  C A Stratakis; L S Kirschner; J A Carney
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

4.  Genotype-phenotype analysis in multiple endocrine neoplasia type 1.

Authors:  Maria A Kouvaraki; Jeffrey E Lee; Suzanne E Shapiro; Robert F Gagel; Steven I Sherman; Rena V Sellin; Gilbert J Cote; Douglas B Evans
Journal:  Arch Surg       Date:  2002-06

5.  The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells.

Authors:  Yoshitaka Sayo; Koji Murao; Hitomi Imachi; Wen Ming Cao; Makoto Sato; Hiroaki Dobashi; Norman C W Wong; Toshihiko Ishida
Journal:  Endocrinology       Date:  2002-06       Impact factor: 4.736

6.  Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.

Authors:  Bruno Vergès; Françoise Boureille; Pierre Goudet; Arnaud Murat; Albert Beckers; Geneviève Sassolas; Patrick Cougard; Béatrice Chambe; Corinne Montvernay; Alain Calender
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

7.  Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity.

Authors:  Juan Lopez-Egido; Janet Cunningham; Mikael Berg; Kjell Oberg; Erik Bongcam-Rudloff; Anders Gobl
Journal:  Exp Cell Res       Date:  2002-08-15       Impact factor: 3.905

8.  Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.

Authors:  Márta Korbonits; Harvinder S Chahal; Gregory Kaltsas; Suzanne Jordan; Yulduz Urmanova; Zamira Khalimova; Philip E Harris; William E Farrell; Francois-Xavier Claret; Ashley B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

9.  Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1.

Authors:  Jeremy J O Turner; Poloko D Leotlela; Anna A J Pannett; Simon A Forbes; J H Duncan Bassett; Brian Harding; Paul T Christie; David Bowen-Jones; Sian Ellard; Andrew Hattersley; Charles E Jackson; Richard Pope; Oliver W Quarrell; Richard Trembath; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours.

Authors:  Gregory A Kaltsas; Blerina Kola; Ninetta Borboli; Damian G Morris; Maria Gueorguiev; Frankie M Swords; Sándor Czirják; Lawrence S Kirschner; Constantine A Stratakis; Márta Korbonits; Ashley B Grossman
Journal:  Clin Endocrinol (Oxf)       Date:  2002-10       Impact factor: 3.478

View more
  16 in total

Review 1.  Signs and genetics of rare cancer syndromes with gastroenterological features.

Authors:  William Bruno; Giuseppe Fornarini; Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

Review 2.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.

Authors:  Yuichi Nagata; Naoko Inoshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Takeo Iwata; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 4.  MEN4 and CDKN1B mutations: the latest of the MEN syndromes.

Authors:  Rami Alrezk; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2017-08-19       Impact factor: 5.678

Review 5.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

6.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

Review 7.  Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 8.  Genetics of gigantism and acromegaly.

Authors:  Fady Hannah-Shmouni; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Growth Horm IGF Res       Date:  2016-08-10       Impact factor: 2.372

9.  Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study.

Authors:  Francesco Ferraù; P D Romeo; S Puglisi; M Ragonese; M L Torre; C Scaroni; G Occhi; E De Menis; G Arnaldi; F Trimarchi; S Cannavò
Journal:  Endocrine       Date:  2016-01-27       Impact factor: 3.633

Review 10.  Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.

Authors:  José Miguel Hinojosa-Amaya; César Ernesto Lam-Chung; Daniel Cuevas-Ramos
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.